— Know what they know.
Not Investment Advice

AKBA NASDAQ

Akebia Therapeutics, Inc.
1W: -9.7% 1M: -28.2% 3M: -13.6% YTD: -34.2% 1Y: -65.1% 3Y: -2.9% 5Y: -70.4%
$1.02
+0.00 (+0.00%)
 
Weekly Expected Move ±11.9%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 29 · $273.6M mcap · 262M float · 1.38% daily turnover · Short 31% of daily vol

📊 Key Metrics

TTM
$232M
Revenue
+25.7% YoY
$-21M
Net Income
+54.7% YoY
$60M
Free Cash Flow
+272.1% YoY
76.4%
Gross Margin
-8.8%
Op. Margin
-16.9%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE247.5%
ROA-6.9%
ROIC6.5%

Valuation

P/E-13.3
P/B10.0
EV/EBITDA127.3

Leverage

Debt/Equity6.63
Current Ratio1.13
Interest Cov.0.2x

Quality Scores

Piotroski F4/9
Altman Z-4.91
Beneish M-2.89

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms